Relay Therapeutics Stock Price Jumps 6.4%

Analysts Remain Bullish on Biotech Firm's Prospects

Apr. 2, 2026 at 3:50pm

Got story updates? Submit your updates here. ›

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) rose 6.4% on Thursday, trading as high as $11.18 per share. The biotech firm, headquartered in Cambridge, Massachusetts, has seen its stock price increase as Wall Street analysts maintain a positive outlook on the company's future performance.

Why it matters

Relay Therapeutics' stock price movement is closely watched by investors as the company continues to develop its pipeline of precision cancer therapies using its proprietary computational drug discovery platform. The 6.4% jump in share price signals growing confidence in the company's ability to bring innovative treatments to market.

The details

The stock's rise came on trading volume of 153,372 shares, down significantly from the average daily volume of 2.4 million shares. Several Wall Street analysts have issued positive ratings and price targets on Relay Therapeutics, with the consensus rating being a 'Moderate Buy' and an average price target of $18.00.

  • Relay Therapeutics stock closed at $10.77 on the previous trading day.
  • The stock traded as high as $11.18 on Thursday before closing at $11.46.

The players

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for cancer using its proprietary computational drug discovery platform.

Wells Fargo & Company

A major Wall Street investment bank that has boosted its price target on Relay Therapeutics stock to $17.00 and maintained an 'Overweight' rating.

Guggenheim

An investment firm that has increased its price target on Relay Therapeutics to $22.00 and reiterated a 'Buy' rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“We remain bullish on Relay Therapeutics' long-term prospects as the company continues to advance its innovative pipeline of precision cancer therapies.”

— Analyst

“Relay Therapeutics' unique drug discovery platform positions the company well to deliver meaningful breakthroughs in oncology.”

— Analyst

What’s next

Investors will be closely watching Relay Therapeutics' upcoming earnings report and any pipeline updates as the company works to bring its novel cancer treatments to market.

The takeaway

Relay Therapeutics' stock price surge reflects growing Wall Street confidence in the company's ability to leverage its computational drug discovery capabilities to develop transformative cancer therapies. As the biotech firm continues to advance its pipeline, its stock could see further upside.